CR-6086 is under clinical development by Rottapharm Biotech and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CR-6086’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CR-6086 overview
CR-6086 is under development for the treatment of rheumatoid arthritis and pMMR-MSS Metastatic Colorectal Cancer. It is orally administered as a form of capsule. The drug candidate is a prostaglandin E receptor 4 (EP4 or prostaglandin E2 receptor EP4 subtype) antagonist. It was also under development for osteoarthritis.
Rottapharm Biotech overview
Rottapharm Biotech (Rottapharm), a subsidiary of Fidim Srl is a drug discovery and development company that develops novel new chemical entities and biotherapeutics such as monoclonal antibodies. The company’s pipeline product portfolio includes CR6086, CRB0017, CR4056, and CRB0089. It offers products for the treatment of rheumatic diseases such as rheumatoid arthritis and osteoarthritis. Rottapharm develops therapies based on its proprietary technology platform for the generation and selection of monoclonal antibodies. The company’s drug discovery and development includes new target validation; pharmacological and pharmacokinetic characterization of novel drug candidates, development of animal models and design of innovative clinical trials. Rottapharm is headquartered in Monza, Italy.
For a complete picture of CR-6086’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
